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INTRODUCTION
 • Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening, progressive disease resulting from chronic, 
uncontrolled complement activation. It is characterized by systemic thrombotic microangiopathy (TMA) leading to renal 
damage and, frequently, damage to other end organs.
 • The efficacy and safety of eculizumab has been proven in 2 prospective Phase 2 trials in patients with evidence of 
progressing TMA and those with long disease duration and chronic kidney disease.1
 • Plasma exchange and infusion (PE/PI) has been used historically to manage aHUS2; however, evidence shows that PE/PI 
affords limited clinical benefit.2 
 – Within 1 year of aHUS diagnosis, up to 65% of patients managed with PE/PI sustain permanent renal damage, 
progress to end-stage renal disease (ESRD), or die.3
STUDY RATIONALE
 • Eculizumab (Soliris®; Alexion Pharmaceuticals, Inc., Cheshire, CT), a terminal complement inhibitor, is a humanized 
monoclonal antibody that binds with high affinity to the human C5 complement protein, blocking the generation of  
pro-inflammatory C5a and C5b-9.1 It is the first and only approved treatment for aHUS in pediatric and adult patients.4
 • Multiple published cases have reported the efficacy of eculizumab in treating pediatric patients with aHUS,5-9 yet, to 
date, no prospective trial of alternate treatment options has ever been conducted in children with aHUS.
 • In addition, a previous retrospective study demonstrated the efficacy of eculizumab in a pediatric population with aHUS 
in a clinical practice setting.7
 • Eculizumab has, therefore, been recommended as first-line therapy in children with aHUS.9
 • Herein, we report safety and efficacy results at 26 weeks from the first prospective trial of pediatric patients with aHUS. 
METHODS
Study Design 
 • Open-label, single-arm, multicenter, multinational, interventional clinical trial.
 • Primary outcome
 – Proportion of patients who achieved complete TMA response during 26 weeks, defined as:
 • Platelet count normalization (≥150 x 109/L).
 • Normalization of lactate dehydrogenase (LDH; < upper limit of the normal range [ULN]).
 • ≥25% improvement in serum creatinine (SCr) from baseline.
 – All 3 parameters had to be met on 2 consecutive measurements obtained ≥4 weeks apart.
 • Secondary outcomes included:
 – Hematologic normalization (platelet count normalization [≥150 x 109/L] and LDH normalization [LDH < ULN]) sustained 
for ≥2 consecutive measurements obtained ≥4 weeks apart.
 – TMA event-free status:
 • No decrease in platelet count >25% from baseline, no PE/PI, and no new dialysis.
 – Hemoglobin increase of ≥20 g/L from baseline sustained for ≥2 consecutive measurements obtained ≥4 weeks apart.
 – ≥25% decrease in SCr from baseline (sustained for ≥2 consecutive measurements obtained ≥4 weeks apart).
 – Change from baseline in estimated glomerular filtration rate (eGFR).
 – eGFR improvement ≥15 mL/min/1.73 m2 from baseline sustained for ≥2 consecutive measurements obtained  
≥4 weeks apart.
 – Change in health-related quality of life (as measured by Pediatric FACIT-F).
 – Pharmacokinetic/pharmacodynamic (PK/PD) measures.
Inclusion Criteria 
 • Pediatric patients with aHUS aged 1 month to <18 years with a body weight ≥5 kg.
 • Platelet count at screening and baseline visit <150 x 109/L.
 • Exhibited signs or symptoms of hemolysis at start of current aHUS episode:
 – LDH ≥1.5 x ULN.
 – Hemoglobin ≤ lower limit of normal range (LLN).
 – Fragmented RBC with a negative Coombs test.
 • SCr ≥97th percentile for age at screening.
 • No requirement for identified complement mutation or antibody.
 • Patients must have been vaccinated against Neisseria meningitidis, pneumococcus, and haemophilus (as per the 
vaccine label) ≥14 days prior to study drug initiation or otherwise be protected by prophylactic antibiotics for 14 days 
after meningococcus vaccination. Due to unavailability of a vaccine for under 2 years, patients in this age group were  
to receive antibiotic prophylaxis throughout the treatment period.
Exclusion Criteria 
 • Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy for ESRD).
 • Shiga toxin–producing Escherichia coli (STEC-HUS) infection.
 • Genetic or acquired severe ADAMTS-13 deficiency (ADAMTS-13 activity <5% [as measured during the screening  
period of the trial]).
 • PE/PI for >5 weeks prior to enrollment.
 • Prior eculizumab use or hypersensitivity to eculizumab, to murine proteins, or to 1 of the excipients.
Dosing
 • Fixed doses of eculizumab were administered intravenously based on pre-specified body weight cohorts.
 • Eculizumab induction and maintenance dosing regimens are described in Table 1.
Table 1. Schedule of Eculizumab Dose Administration Based on Weight
Weight Cohort Induction Maintenance
≥40 kg 900 mg weekly x 4 1200 mg week 5; 1200 mg q2 weeks
30 to <40 kg 600 mg weekly x 2 900 mg week 3; 900 mg q2 weeks
20 to <30 kg 600 mg weekly x 2 600 mg week 3; 600 mg q2 weeks
10 to <20 kg 600 mg weekly x 1 300 mg week 2; 300 mg q2 weeks
5 to <10 kg 300 mg weekly x 1 300 mg week 2; 300 mg q3 weeks
Statistical Analysis
 • The primary efficacy endpoint was the proportion of patients with a complete TMA response during the first 26 weeks of 
the study period in the intent-to-treat (ITT) population. 
 – The ITT population was defined as all patients who signed an informed consent and received ≥1 dose of eculizumab.
 • Proportion of patients with eGFR change from baseline ≥15 mL/min/1.73 m2 was calculated similarly to primary endpoint 
(as per the statistical analysis plan). While the patient was on dialysis, the eGFR value was set at 10 mL/min/1.73 m2.
 • All statistical tests were assessed at the 2-sided α = 5% level without adjusting for multiplicity. The primary analysis was 
assessed at the 1-sided α = 5% level.
 • For the composite endpoints, if the post-baseline or baseline data for any component were missing, then the patient was 
treated as censored at the last follow-up day. Patients who did not have valid baseline values or any valid post-baseline 
values were also treated as a failure for endpoints.
 • The eGFR was calculated using the Schwartz formula: eGFR (mL/min/1.73 m2) = [0.413 x height (cm)] / SCr (mg/dL)].
RESULTS
Patient Disposition 
 • Twenty-two pediatric patients were treated with eculizumab and 19 patients (86%) completed the 26-week study period 
(Table 2).
Table 2. Trial C10-003: Patient Disposition
Category
Intent-to-Treat Population
(N=22)
Enrolled 27
Not treated, n (%)
     Positive test for Shiga toxin
     Platelet count normalized
     Final diagnosis not aHUS
     Unspecified reasons
5 (19) 
1
1
2
1
Treated 22
Discontinued eculizumab treatment before completing  
26-week study period, n (%)
3 (14)
Completed 26-week study period, n (%) 19 (86)
Reason for withdrawal, n (%)
     Confirmed diagnosis of STEC-HUS
     Serious adverse event (agitation) 
     Family request to withdraw patient
 
1 (5)
1 (5)
1 (5)
aHUS, atypical hemolytic uremic syndrome; STEC-HUS, Shiga toxin–producing E. coli infection.
Patient Demographics and Baseline Laboratory Values (Table 3)
 • The median duration from the onset of the clinical manifestation to screening was 6 days. 
 • A total of 12 patients (55%) had no PE/PI prior to eculizumab initiation.
 • Eleven patients (50%) were on dialysis at baseline.
 • Twenty patients (91%) had eGFR <90 mL/min/1.73 m2.
Table 3. Trial C10-003: Demographics and Baseline Laboratory Values
Category
Intent-to-Treat Population
(N=22)
Age at first infusion (years) – median (range)  6.5 (0.0–17.0) 
Age, n (%) 
     1 month to <23 months
      ≥23 months to <5 years
     ≥5 to <12 years 
     ≥12 to <18 years
 
5 (22.7)
5 (22.7)
8 (36.4)
4 (18.2)
Female gender, n (%) 10 (45)
Race, n (%)
     Asian
     Black or African American
     Caucasian
     Other
2 (9)
0 (0)
18 (82)
2 (9)
Patient-reported family history of aHUS, n (%) 6 (27)
Identified genetic mutations, n (%)
     Anti-Complement Factor Antibody: Factor H autoantibody positive
     Anti-Complement Factor Antibody: Factor H autoantibody positive, CFHR1, CFHR3
     Complement Protein 3 (C3) Gain-of-Function Mutation
     Factor H
     Factor I
     Membrane Cofactor Protein (MCP)
10 (45)
1 (5)
1 (5)
1 (5)
2 (9)
2 (9)
 3 (14)
Patients with CFHR1/3 polymorphism, n (%) 1 (5)
No identified mutation, n (%) 11 (50)
Median duration (range) from aHUS diagnosis until screening (months) 0.6 (0.03–191)
Median duration (range) from current manifestation to first dose (months) 0.20 (0.03–4.3)
First clinical TMA manifestation, n (%) 16 (72.7)
No PE/PI during current manifestation, n (%) 12 (55)
Dialysis at baseline, n (%)* 11 (50)
Prior renal transplant, n (%) 2 (9)
Platelet count (x 109/L) – mean (SD) 87.5 (42.3)
Patients with platelet count <150 x 109/L, n (%) 22 (100)
LDH (U/L) – mean (SD) 1943.7 (1824.4)
LDH > ULN 19 (86.4)
Hemoglobin concentration (g/L) – mean (SD) 80.2 (15.3)
Serum creatinine (umol/L) – mean (SD) 154.5 (116.43)
eGFR (mL/min/1.73 m2) – mean (SD) 32.7 (30.37)
eGFR (mL/min/1.73 m2), n (%)
     <15
     15–29
     30–44
     45–59
     60–89
     ≥90
10 (45.5)
4 (18.2)
2 (9.1)
2 (9.1)
2 (9.1)
2 (9.1)
aHUS, atypical hemolytic uremic syndrome; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; PE/PI, plasma exchange/plasma infusion;  
SD, standard deviation; TMA, thrombotic microangiopathy; ULN, upper limit of normal.
*One patient who was on dialysis at baseline discontinued dialysis during the baseline window prior to the first dose of eculizumab.
Efficacy Outcomes 
Primary Outcome: Complete TMA Response Through 26 Weeks 
 • Complete TMA response was achieved in 14 of 22 patients (64%; 95% CI: 41–83) from baseline to 26 weeks (Figure 1). 
 – Median (range) time to complete TMA response was 60.0 (7.0–153.0) days.
Hematologic Outcomes Over 26 Weeks
 • Twenty-one of 22 patients (95%; 95% CI: 77–99.9) achieved TMA event-free status during 26 weeks.
 • Hematologic normalization was observed in 18 of 22 patients (82%; 95% CI: 60–95) (Figure 1) after 26 weeks.
 • Twenty-one of 22 patients (95%; 95% CI: 77–99.9) achieved platelet count normalization from baseline (Figure 1). 
 – Median (range) time to platelet count normalization was 7.0 (1.0–80.0) days.
 – Mean (SD) improvement in platelet count from baseline was 164 (76.4) x 109/L (Figure 2).
 • Eighteen of 22 patients (82%; 95% CI: 60–95) achieved LDH normalization from baseline to 26 weeks of eculizumab 
treatment (Figure 1).
 • Fifteen of 22 patients (68%; 95% CI: 45–86) had improvement in hemoglobin concentration of ≥20 g/L from baseline 
through 26 weeks.
 • Of 10 patients on PE/PI at baseline, all (100%) discontinued by the end of the 26-week study.
Figure 1. Proportion of Patients Achieving Complete TMA Response and Hematologic, 
Platelet Count, and LDH Normalization During 26 Weeks
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Figure 2. Mean Platelet Count Improvement
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Renal Outcomes Over 26 Weeks
 • Nineteen patients (86%) had eGFR improvement ≥15 mL/min/1.73 m2 from baseline through 26 weeks (Table 4).
 • Mean improvement from baseline in eGFR was 64 mL/min/1.73 m2. Decrease in SCr (≥25%) was observed in 16 patients 
(73%) (Table 4, Figure 3).
 • Of the 11 patients on dialysis at baseline, 9 discontinued during the 26-week study period (Table 4).
 – Of the 11 patients not on dialysis at baseline, 11 (100%) remained dialysis-free during 26 weeks.
Table 4. Summary of Renal Outcomes
Parameter
Intent-to-Treat Population
(N=22)
eGFR improvement from baseline ≥15 mL/min/1.73 m2, n (%) 19 (86)
Serum creatinine decrease ≥25%, n (%) 16 (73)
CKD improvement ≥1 stage from baseline, n (%) 17 (77)
Patients on dialysis at baseline (n=11) who discontinued during study, n (%) 9/11 (82)
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate. 
Figure 3. Mean Improvement in eGFR Over 26 Weeks
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eGFR, estimated glomerular filtration rate. 
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†P≤0.0001.
Bars represent standard error of the mean.
Improvement in Health-Related Quality of Life 
 • The Pediatric FACIT-F LS mean change from baseline to data cutoff was 19.7 (range, 15.6–23.7), which was statistically 
significant (P<0.0001).
Pharmacokinetics and Pharmacodynamics
 • The population PK analysis suggests that the approved eculizumab pediatric dosing regimen in Study C10-003 resulted 
in concentrations within the target concentration range (50–700 μg/mL) during the induction and maintenance phases for 
all age cohorts. 
 • Results from the population PK/PD analysis demonstrate that the dosing strategy of eculizumab resulted in complete 
terminal complement inhibition (as measured by hemolytic activity) in all but 1 patient.
Eculizumab Was Safe and Well Tolerated Over the 26-Week Study Period
 • There were no deaths or meningococcal infections reported during the 26-week study period.
 • Twenty of 22 patients enrolled (91%) reported at least 1 treatment-emergent adverse event (TEAE), the majority  
of which were mild to moderate in severity (Table 5).
 – None of the infection-related TEAEs were considered severe.
 • Thirteen of 22 patients (59%) reported at least 1 serious TEAE (Table 5).
 – One patient discontinued due to agitation, a serious TEAE.
 – One patient had a human anti-human antibody response, and continued eculizumab treatment without apparent 
adverse effect. 
Table 5. Safety of Eculizumab Treatment and Summary of TEAEs
Intent-to-Treat Population
(N=22)
TEAEs (frequency ≥20%), n (%)
Fever 11 (50)
Cough 8 (36)
Abdominal pain 7 (32)
Diarrhea 7 (32)
Upper respiratory tract infection 7 (32)
Vomiting 6 (27)
Nasopharyngitis 6 (27)
Patients with any serious TEAE, n (%) 13 (59)
Severity, n (%)
Mild
Moderate
Severe
3 (14) 
7 (32) 
3 (14) 
Relationship to eculizumab treatment, n (%)
Unrelated 
Possible
10 (45)
3 (14)
SAEs occurring in 2 or more patients, n (%)
Fever 2 (9)
Gastroenteritis viral 2 (9)
Upper respiratory tract infection 2 (9)
Hypertension 2 (9)
SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.
CONCLUSIONS
 • In this, the first-ever prospective trial of pediatric patients with aHUS, the use of eculizumab led to rapid and sustained 
improvement in platelet counts and significant and continuous improvement over time in eGFR.
 • Most patients (73%) were newly diagnosed.
 • The median time from current manifestation to first dose of eculizumab was 6 days.
 • Twelve of the 22 patients (55%) received no PE/PI prior to treatment with eculizumab.
 • Complete TMA response – the primary endpoint – was achieved in 14 of 22 patients (64%) after 26 weeks.
 • A total of 21 patients (95%) achieved platelet count normalization from baseline to 26 weeks.
 • Nineteen patients (86%) had eGFR improvement ≥15 mL/min/1.73 m2 after 26 weeks; 64 mL/min/1.73 m2 mean 
improvement in eGFR from baseline.
 • Eculizumab treatment facilitated discontinuation of dialysis and PE/PI.
 – Of the 10 patients receiving PE/PI at baseline, all discontinued.
 – Nine of 11 patients on dialysis at baseline were able to discontinue by 26 weeks.
 – Of the 11 patients not on dialysis at baseline, 11 (100%) remained dialysis-free through 26 weeks.
 • There were no meningococcal infections reported, and no new safety concerns arose during the 26-week study period.
 • The safety and efficacy demonstrated in the trial confirm the results observed in the C09-001 pediatric retrospective 
study,10 as well as the published Phase 2 prospective trials.1,7 
 • These results also support the recommendation that eculizumab be used as first-line treatment in pediatric patients 
with aHUS.9
 • The trial is ongoing.
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